Doença falciforme
Manejo da crise oclusiva vascular e síndrome torácica aguda
Manejo da dor
What is the best pharmacologic treatment for sickle cell disease pain crises? (abre nova janela)
Fonte: Ann Emerg Med 2012;59(6):515-6.
Indexado: PubMed 22221839
DOI: 10.1016/j.annemergmed.2011.11.026
https://www.ncbi.nlm.nih.gov/pubmed/22221839 (abre nova janela)
Update on pain management in sickle cell disease. (abre nova janela)
Fonte: Hemoglobin 2011;35(5-6):520-9.
Indexado: PubMed 21910604
DOI: 10.3109/03630269.2011.610478
https://www.ncbi.nlm.nih.gov/pubmed/21910604 (abre nova janela)
Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. (abre nova janela)
Fonte: Thromb Haemost 2007;98(2):392-6.
Indexado: PubMed 17721622
https://www.ncbi.nlm.nih.gov/pubmed/17721622 (abre nova janela)
Adult emergency department patients with sickle cell pain crisis: results from a quality improvement learning collaborative model to improve analgesic management. (abre nova janela)
Fonte: Acad Emerg Med 2012;19(4):430-8.
Indexado: PubMed 22506947
DOI: 10.1111/j.1553-2712.2012.01330.x
https://www.ncbi.nlm.nih.gov/pubmed/22506947 (abre nova janela)
Terapia de hidratação (manejo de fluidos)
Management of sickle cell disease. (abre nova janela)
Fonte: BMJ 2008;337:a1397.
Indexado: PubMed 18779222
https://www.ncbi.nlm.nih.gov/pubmed/18779222 (abre nova janela)
Fluid replacement therapy for acute episodes of pain in people with sickle cell disease. (abre nova janela)
Fonte: Cochrane Database Syst Rev 2012;(6):CD005406.
Indexado: PubMed 22696351
DOI: 10.1002/14651858.CD005406.pub3
https://www.ncbi.nlm.nih.gov/pubmed/22696351 (abre nova janela)
Suplementação de oxigênio
Low flow nocturnal oxygen therapy does not suppress haemoglobin levels or increase painful crises in sickle cell disease. (abre nova janela)
Fonte: Br J Haematol 2013;161(3):455-6.
Indexado: PubMed 23419066
DOI: 10.1111/bjh.12254
https://www.ncbi.nlm.nih.gov/pubmed/23419066 (abre nova janela)
Guidelines for the management of the acute painful crisis in sickle cell disease. (abre nova janela)
Fonte: Br J Haematol 2003;120(5):744-52.
Indexado: PubMed 12614204
https://www.ncbi.nlm.nih.gov/pubmed/12614204 (abre nova janela)
Hyperbaric oxygen therapy for vaso-occlusive crises in nine patients with sickle-cell disease. (abre nova janela)
Fonte: Diving Hyperb Med 2012;42(2):82-4.
Indexado: PubMed 22828815
https://www.ncbi.nlm.nih.gov/pubmed/22828815 (abre nova janela)
Terapia respiratória e antibiótica
Safety of purified poloxamer 188 in sickle cell disease: phase I study of a non-ionic surfactant in the management of acute chest syndrome. (abre nova janela)
Fonte: Hemoglobin 2004;28(2):85-102.
Indexado: PubMed 15182051
https://www.ncbi.nlm.nih.gov/pubmed/15182051 (abre nova janela)
Incentive spirometry to prevent acute pulmonary complications in sickle cell diseases. (abre nova janela)
Fonte: N Engl J Med 1995;333(11):699-703.
Indexado: PubMed 7637747
DOI: 10.1056/NEJM199509143331104
https://www.ncbi.nlm.nih.gov/pubmed/7637747 (abre nova janela)
Continuous inhaled nitric oxide therapy in a case of sickle cell disease with multiorgan involvement. (abre nova janela)
Fonte: J Investig Med 2008;56(8):1023-7.
Indexado: PubMed 19050460
DOI: 10.2310/JIM.0b013e31818cb612
https://www.ncbi.nlm.nih.gov/pubmed/19050460 (abre nova janela)
Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. (abre nova janela)
Fonte: N Engl J Med 2000;342(25):1855-65.
Indexado: PubMed 10861320
DOI: 10.1056/NEJM200006223422502
https://www.ncbi.nlm.nih.gov/pubmed/10861320 (abre nova janela)